Dcp1 Inhibitors

Dcp1 inhibitors primarily function through targeting mRNA synthesis, splicing, export, or translation processes, thereby indirectly modulating the substrate pool available for Dcp1-mediated decay. Chemicals such as Actinomycin D and α-Amanitin, which inhibit RNA polymerase, reduce the rate of mRNA synthesis. Consequently, the pool of mRNA that would undergo decay is restricted. Similarly, Flavopiridol acts on CDK9, inhibiting the phosphorylation of RNA polymerase II, and leading to a reduction in newly transcribed mRNA. Leptomycin B interferes with the export of certain mRNAs, thus affecting Dcp1's range of action within the cytoplasm.

Other inhibitors specifically target the splicing machinery, directly affecting the constitution of mRNA that would be acted upon by Dcp1. Meayamycin B and Pladienolide B inhibit the spliceosome, leading to intron retention and aberrantly spliced mRNAs that accumulate in the nucleus, limiting Dcp1 action. Compounds like Puromycin and Anisomycin, affecting the translation process, lead to premature termination of translation or peptide bond formation. This results in mRNA transcripts that are likely to be recognized for accelerated decay, thereby affecting Dcp1's regulatory role in mRNA turnover.